View printer-friendly version

  • SleepCheck now validated and available for download on select Android devices – additional devices to be rolled out progressively
  • SleepCheck is the world’s first direct-to-consumer regulatory-approved screening test for sleep apnoea, allowing users to accurately self-assess their risk of sleep apnoea at home
  • SleepCheck for Android now available in 36 markets – unlocking a large opportunity for ResApp

Brisbane, Australia, 29 December 2020 — ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, is pleased to advise that it has launched SleepCheck, its direct-to-consumer smartphone app for the self-assessment of sleep apnoea, on select Android devices.

Sleep apnoea is a common sleep breathing disorder where a person repeatedly stops breathing or has periods of shallow breathing during sleep. Globally, it has been estimated that 936 million people have sleep apnoea and up to 80% of people suffering from moderate or severe sleep apnoea are undiagnosed.

SleepCheck is a smartphone application that uses the smartphone’s microphone to record and analyse an adult’s breathing and snoring patterns overnight. In a large clinical study, SleepCheck’s algorithms were shown to accurately assess a person’s risk of sleep apnoea when compared to a full sleep test. SleepCheck has achieved CE Mark in Europe and is TGA approved for ARTG listing in Australia as a class I medical device.

SleepCheck version 1.4 is now available on the App Store for iPhone and Google Play for Android. SleepCheck 1.4 on Android supports Samsung Galaxy S9, S9+, S10, S10+ and S20 phones, with support for additional devices anticipated in the near term. Following ResApp’s recent partnership with Australia’s largest consumer healthcare network HealthEngine (refer ASX announcement: 21 October 2020), version 1.4 also includes a convenient way for Australian users to book an appointment with a general practitioner directly from the app.

CEO and Managing Director Dr Tony Keating said: “The Android device market is large and well-established, with over 2.5 billion devices globally and we are very pleased to have launched SleepCheck to cater for these users. SleepCheck is now available on Google Play in 36 countries, including large markets like Europe, Hong Kong and Singapore.

“The launch follows extensive internal testing to ensure that SleepCheck version 1.4 delivers a best-in-class experience and solution for people to accurately self-assess their risk of sleep apnoea.

“Uptake on iOS continues, and we expect Android download rates to add to our growing user base. The launch will also coincide with a marketing campaign in Australia and the UK to drive product awareness, which will allow ResApp to grow its market share and engage with other potential industry partners.

“SleepCheck is a very unique offering with broad reach and availability and it has considerable potential in the sleep health space. We are excited about the ongoing opportunities it will present for ResApp.”


About ResApp Health Limited
ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of the respiratory disease. ResApp’s machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp’s regulatory-approved and clinically validated products include ResAppDx, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department and primary care settings; and SleepCheck, a smartphone application which allows consumers to self-assess their risk of sleep apnoea. Both products are CE Marked in Europe and TGA approved in Australia. For more information, please visit

Contacts for ResApp Health
Dr Tony Keating
CEO and Managing Director
+61 430 180 659

Brian Leedman
VP, Corporate Affairs
+61 412 281 780

ResApp Logo White

ResApp Health Limited
ABN 51 094 468 318
Level 12, 100 Creek St,
Brisbane, QLD 4000, Australia

Follow Us

© 2022 ResApp Health Limited. All rights reserved.